Search: onr:"swepub:oai:lup.lub.lu.se:dbd70585-c136-47c1-b75a-184b69ddf7dd" >
Behandling af reuma...
Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation
-
Bendtzen, Klaus (author)
-
- Geborek, Pierre (author)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Svenson, Morten (author)
-
show more...
-
Larsson, Lotta (author)
-
Kapetanovic, Meliha C (author)
-
- Saxne, Tore (author)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine
-
show less...
-
(creator_code:org_t)
- 2007
- 2007
- Danish.
-
In: Ugeskrift for Laeger. - 0041-5782. ; 169:5, s. 420-423
- Related links:
-
http://www.ugeskrift... (free)
-
show more...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.
- Abstract in Danish Infliximab er effektiv ved reumatoid artritis (RA), men behandlingssvigt er hyppige. Sera fra 106 RA-patienter monitoreredes med en radioimmunoassay (RIA) for funktionel infliximab og en RIA for anti-infliximab-antistof. S-infliximab varierede betydeligt, f.eks. 0-22 μg/ml forud for tredje infusion, og efter seks måneder var 44% antistofpositive. Lav S-infliximab var forbundet med antistofudvikling og senere terapisvigt, og høje antistofniveauer kunne relateres til dosisøgning, bivirkninger og terapiophør. Farmakologisk monitorering kan formentlig optimere behandlinger med anti-tumornekrose-antistof.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database